Healthleap Raises $38M to Flag Hospital Patients Who May Need Review

Healthleap has raised $38 million to grow an AI business built around a narrower task than diagnosis: flagging hospital patients who may need closer clinical review. The financing combines seed and Series A rounds. CEO Josiah Meyer told TechCrunch the platform already screens for conditions including malnutrition and delirium in more than 50 hospitals.

Sequoia Capital and First Round Capital co-led the $8 million seed round; Hummingbird Ventures led the $30 million Series A. Healthleap did not disclose its valuation. The company plans to put the money into engineering, product, sales and customer success while adding support for more conditions.

Reading the notes alongside the numbers

Founded in South Africa in 2022 by siblings Jemima and Josiah Meyer, Healthleap began with a nutrition tool Jemima built for dietitians. It later shifted toward a broader screening platform for hospitalized patients whose conditions may not have been identified early enough.

The software connects to a hospital’s electronic health record system. Language models extract details from clinicians’ notes, such as recent weight loss or difficulty swallowing. Meyer says the approach distinguishes mentions that affirm a clinical sign from those that say it is absent.

Those findings feed risk models alongside structured information such as lab results and vital signs. Meyer says the system analyzes every adult inpatient’s record nightly, then writes a risk score into the care team’s existing workflow each morning. A dashboard provides additional patient-trend information. Healthleap says the software does not diagnose patients.

The commercial pitch is measurable savings

Meyer says hospital partners grew from three to more than 50 over the past year, while revenue increased more than tenfold. He did not disclose revenue figures. Named customers include Penn Medicine, Cedars-Sinai, Intermountain, Houston Methodist and Emory Healthcare.

Healthleap sells three-year contracts priced according to a hospital’s licensed bed count and also uses outcome-based pricing. Meyer says its return calculations use financial benefits that hospital finance teams validate and attribute to Healthleap.

At the Hospital of the University of Pennsylvania, Healthleap says its malnutrition program produced $23.8 million in annualized financial impact: $6.3 million from additional reimbursement and $17.5 million from shorter hospital stays. Those are company-reported financial results, not an independent assessment of the program’s clinical performance.

Broader screening still needs validation

Beyond its current malnutrition and delirium screening, Meyer says Healthleap has built programs undergoing further clinical validation for:

• Aspiration pneumonia.
• Pressure ulcers.
• Readmission risk for congestive heart failure.

The longer-term ambition is to cover more than 40 major health conditions and move into outpatient and home care. Those are expansion goals, rather than the scope of the hospital service Meyer describes today.